Yvonne Greenstreet
Yvonne Greenstreet is a prominent figure in the field of pharmacology and healthcare industry. She is known for her significant contributions to the development and commercialization of innovative medicines that have had a profound impact on patients' lives.
Early Life and Education[edit | edit source]
Yvonne Greenstreet was born and raised in the United Kingdom. She pursued her undergraduate studies in Medicine at the University of Leeds, where she graduated with honors. She later earned an MBA from INSEAD, one of the world's leading and largest graduate business schools.
Career[edit | edit source]
Greenstreet has over 25 years of experience in the healthcare industry, with a focus on drug development and strategic planning. She began her career at Pfizer, where she held several senior leadership roles, including Senior Vice President and Head of Medicines Development Group for the company's Specialty Care Business.
In 2011, Greenstreet joined GlaxoSmithKline (GSK) as Senior Vice President and Head of Global Medicines Development and Chief Medical Officer. During her tenure at GSK, she led the development of a robust pipeline of innovative medicines and played a key role in the company's strategic business decisions.
In 2016, Greenstreet joined Alnylam Pharmaceuticals as the Chief Operating Officer. At Alnylam, she has been instrumental in the development and commercialization of RNAi therapeutics, a revolutionary approach to treating diseases.
Recognition[edit | edit source]
Greenstreet's contributions to the field of pharmacology have been widely recognized. She was named one of the Top 50 Most Powerful Women in Corporate America by Black Enterprise in 2015 and has been listed in the PharmaVOICE 100, a list of the most inspiring people in the life sciences industry.
See Also[edit | edit source]
References[edit | edit source]
External Links[edit | edit source]
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
